Dominic Jaikaran

Dominic Jaikaran is the President and CEO of Bright Angel Therapeutics. He joined the company in 2018 after playing an instrumental role in the company’s formation. He has over fifteen years of experience in biotechnology and finance. Prior to Bright Angel Therapeutics, Dominic held leadership positions at MaRS Innovation and Diversa Corporation (now BASF), a NASDAQ-listed company in San Diego. He was also a Principal at BDC Venture Capital, focusing on early-stage life science investments.

Dominic holds a PhD in Biological Chemistry and a BSc in Chemistry and Biochemistry, both from the University of Toronto. He also holds an MBA from the Rotman School of Management.